Ultralife Corporation (NASDAQ: ULBI) lifts Q2 margin with record $117.5M backlog
Ultralife Corporation reported Q2 2026 revenues of 47,943 (in thousands), slightly below 48,561 a year earlier, but expanded gross margin to 28.9% from 23.9%. Net income attributable to Ultralife rose to 2,543 (in thousands), or $0.15 per basic and diluted share.
Margin gains were driven by favorable product mix in both segments and a $1,102 IEEPA tariff refund recorded as a reduction of cost of products sold. Q2 adjusted EBITDA was 6,148 (in thousands). Backlog reached a record $117.5 million. Cash was 6,663 with 45,125 of term loan outstanding and no revolver borrowings. Management disclosed that a previously identified material weakness in internal control over financial reporting and related IT general controls remained under remediation as of June 30, 2026.
Positive
- Order backlog reached a record $117.5 million exiting Q2 2026, up from $115.1 million in Q1 2026 and $84.5 million a year earlier, indicating strong contracted demand pipeline.
Negative
- Management reports an ongoing material weakness in internal control over financial reporting and IT general controls, which had not been fully remediated as of June 30, 2026.
Filing Explained
The $100 million shelf is financing capacity, not an issuance; any future takedown still requires a prospectus supplement.
The company’s unaudited Form 10-Q describes an effective shelf registration for
That shelf is financing capacity rather than an issuance or proceeds received; a future sale would require an appropriate prospectus supplement.
The company received cash for the recognized
At
Key Figures
Key Terms
Adjusted EBITDA financial
International Emergency Economic Powers Act regulatory
45X Advanced Manufacturing Production Credit regulatory
Term Loan Facility financial
material weakness regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Ultralife (ULBI) perform financially in Q2 2026?
What drove Ultralife (ULBI)'s margin improvement in Q2 2026?
What is Ultralife (ULBI)'s backlog after Q2 2026?
How leveraged and liquid is Ultralife (ULBI) as of June 30, 2026?
Does Ultralife (ULBI) have any material weaknesses in internal controls?
How did Ultralife (ULBI)'s business segments perform in Q2 2026?
What was Ultralife (ULBI)'s adjusted EBITDA in Q2 2026 and year-to-date?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________ to ____________
Commission file number:
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation or organization)
(Address of principal executive offices) (Zip Code) |
(I.R.S. Employer Identification No.)
( (Registrant’s telephone number, including area code) |
None
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
share |
|
|
|
(Title of each class) |
(Trading Symbol) |
(Name of each exchange on which registered) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐ |
|
|
Non-accelerated filer ☐ |
Smaller reporting company |
|
Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of August 3, 2026, the registrant had
ULTRALIFE CORPORATION AND SUBSIDIARIES
INDEX
|
Page |
||
|
PART I. |
FINANCIAL INFORMATION |
|
|
Item 1. |
Consolidated Financial Statements (unaudited): |
|
|
Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 |
1 |
|
|
Consolidated Statements of Income and Comprehensive Income for the Three and Six-Month Periods Ended June 30, 2026 and June 30, 2025 |
2 |
|
|
Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2026 and June 30, 2025 |
3 |
|
|
Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six-Month Periods Ended June 30, 2026 and June 30, 2025 |
4 |
|
|
Notes to Consolidated Financial Statements (unaudited) |
5 |
|
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
19 |
|
Item 4. |
Controls and Procedures |
28 |
|
PART II. |
OTHER INFORMATION |
|
|
Item 6. |
Exhibits |
30 |
|
Signatures |
31 |
PART I. FINANCIAL INFORMATION
Item 1. CONSOLIDATED FINANCIAL STATEMENTS
|
ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In Thousands except share amounts) (Unaudited) |
|
June 30, 2026 |
December 31, 2025 |
|||||||
| ASSETS | ||||||||
|
Current assets: |
||||||||
|
Cash |
$ | $ | ||||||
|
Trade accounts receivable, net of allowance for expected credit losses of $ |
||||||||
|
Inventories, net |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Total current assets |
||||||||
|
Property, plant and equipment, net |
||||||||
|
Goodwill |
||||||||
|
Other intangible assets, net |
||||||||
|
Deferred income taxes, net |
||||||||
|
Other noncurrent assets |
||||||||
|
Total assets |
$ | $ | ||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | $ | ||||||
|
Current portion of long-term debt |
||||||||
|
Accrued compensation and related benefits |
||||||||
|
Accrued expenses and other current liabilities |
||||||||
|
Total current liabilities |
||||||||
|
Long-term debt, net |
||||||||
|
Deferred income taxes |
||||||||
|
Other noncurrent liabilities |
||||||||
|
Total liabilities |
||||||||
|
Commitments and contingencies (Note 8) |
|
|
||||||
|
Stockholders’ equity: |
||||||||
|
Preferred stock – par value $.10 per share; authorized |
||||||||
|
Common stock – par value $.10 per share; authorized |
||||||||
|
Capital in excess of par value |
||||||||
|
Accumulated deficit |
( |
) | ( |
) | ||||
|
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
|
Treasury stock - at cost; |
( |
) | ( |
) | ||||
|
Total Ultralife Corporation equity |
||||||||
|
Non-controlling interest |
||||||||
|
Total stockholders’ equity |
||||||||
|
Total liabilities and stockholders’ equity |
$ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(In Thousands except per share amounts)
(Unaudited)
|
Three-month period ended |
Six-month period ended |
|||||||||||||||
|
June 30, 2026 |
June 30, 2025 |
June 30, 2026 |
June 30, 2025 |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Cost of products sold |
||||||||||||||||
|
Gross profit |
||||||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Research and development |
||||||||||||||||
|
Selling, general and administrative |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Operating income |
||||||||||||||||
|
Other expense (income): |
||||||||||||||||
|
Interest and financing expense |
||||||||||||||||
|
Miscellaneous (income) expense |
( |
) | ( |
) | ||||||||||||
|
Total other expense |
||||||||||||||||
|
Income before income taxes |
||||||||||||||||
|
Income tax provision |
||||||||||||||||
|
Net income |
||||||||||||||||
|
Net (loss) income attributable to non-controlling interest |
( |
) | ( |
) | ( |
) | ||||||||||
|
Net income attributable to Ultralife Corporation |
||||||||||||||||
|
Other comprehensive income: |
||||||||||||||||
|
Foreign currency translation adjustments |
||||||||||||||||
|
Comprehensive income attributable to Ultralife Corporation |
$ | $ | $ | $ | ||||||||||||
| Net income per share attributable to Ultralife common stockholders – basic | $ | . |
$ | . |
$ | . |
$ | . |
||||||||
|
Net income per share attributable to Ultralife common stockholders – diluted |
$ | . |
$ | . |
$ | . |
$ | . |
||||||||
|
Weighted average shares outstanding – basic |
||||||||||||||||
|
Potential common shares |
||||||||||||||||
|
Weighted average shares outstanding - diluted |
||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
|
ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands) (Unaudited) |
||||||||
|
Six-month period ended |
||||||||
|
June 30, 2026 |
June 30, 2025 |
|||||||
|
OPERATING ACTIVITIES: |
||||||||
|
Net income |
$ | $ | ||||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation |
||||||||
|
Amortization of intangible assets |
||||||||
|
Amortization of financing fees |
||||||||
|
Stock-based compensation |
||||||||
|
Deferred income taxes |
||||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
( |
) | ( |
) | ||||
|
Inventories |
( |
) | ||||||
|
Prepaid expenses and other assets |
||||||||
|
Accounts payable and other liabilities |
( |
) | ||||||
|
Net cash provided by operating activities |
||||||||
|
INVESTING ACTIVITIES: |
||||||||
|
Purchases of property, plant and equipment |
( |
) | ( |
) | ||||
|
Net cash used in investing activities |
( |
) | ( |
) | ||||
|
FINANCING ACTIVITIES: |
||||||||
|
Payments on credit facilities |
( |
) | ( |
) | ||||
|
Debt issuance costs |
( |
) | ||||||
|
Proceeds from exercise of stock options |
||||||||
|
Net cash used in financing activities |
( |
) | ( |
) | ||||
|
Effect of exchange rate changes on cash |
||||||||
|
(DECREASE) INCREASE IN CASH |
( |
) | ||||||
|
Cash, Beginning of period |
||||||||
|
Cash, End of period |
$ | $ | ||||||
|
The accompanying notes are an integral part of these consolidated financial statements. |
|
ULTRALIFE CORPORATION AND SUBSIDIARIES |
|
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY |
|
(In thousands except share amounts) (Unaudited) |
|
Capital |
Accumulated |
|||||||||||||||||||||||||||||||
|
Common Stock |
in Excess |
Other |
Non- |
|||||||||||||||||||||||||||||
|
Number of |
of Par |
Comprehensive |
Accumulated |
Treasury |
Controlling |
|||||||||||||||||||||||||||
|
Shares |
Amount |
Value |
Income (Loss) |
Deficit |
Stock |
Interest |
Total |
|||||||||||||||||||||||||
|
Balance – December 31, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Net income |
||||||||||||||||||||||||||||||||
|
Stock option exercises |
||||||||||||||||||||||||||||||||
|
Stock-based compensation – stock options |
||||||||||||||||||||||||||||||||
|
Stock-based compensation - restricted stock |
||||||||||||||||||||||||||||||||
|
Foreign currency translation adjustments |
||||||||||||||||||||||||||||||||
|
Balance – June 30, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Balance – December 31, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Net income (loss) |
( |
) | ||||||||||||||||||||||||||||||
|
Stock option exercises |
||||||||||||||||||||||||||||||||
|
Stock-based compensation – stock options |
||||||||||||||||||||||||||||||||
|
Stock-based compensation - restricted stock |
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Foreign currency translation adjustments |
||||||||||||||||||||||||||||||||
|
Balance – June 30, 2026 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Balance – March 31, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Net income (loss) |
( |
) | ||||||||||||||||||||||||||||||
|
Stock option exercises |
||||||||||||||||||||||||||||||||
|
Stock-based compensation – stock options |
||||||||||||||||||||||||||||||||
|
Stock-based compensation - restricted stock |
||||||||||||||||||||||||||||||||
|
Foreign currency translation adjustments |
||||||||||||||||||||||||||||||||
|
Balance – June 30, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Balance – March 31, 2026 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
|
Net income (loss) |
( |
) | ||||||||||||||||||||||||||||||
|
Stock option exercises |
||||||||||||||||||||||||||||||||
|
Stock-based compensation – stock options |
||||||||||||||||||||||||||||||||
|
Stock-based compensation - restricted stock |
||||||||||||||||||||||||||||||||
|
Foreign currency translation adjustments |
||||||||||||||||||||||||||||||||
|
Balance – June 30, 2026 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | |||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
ULTRALIFE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands except share and per share amounts)
(Unaudited)
|
1. |
BASIS OF PRESENTATION |
The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2025.
The December 31, 2025 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.
Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.
Recent Business Developments
In connection with the importation of certain raw materials and components used in the manufacture of its products, the Company previously paid tariffs imposed pursuant to the International Emergency Economic Powers Act ("IEEPA"). Such tariff costs were included in inventory and recognized in cost of products sold as the related inventory was sold.
During the second quarter of 2026, the Company received cash refunds of previously paid IEEPA tariffs following legal developments related to the validity of certain IEEPA tariffs and the implementation of refund procedures by U.S. Customs and Border Protection. The Company accounts for IEEPA tariff refunds as gain contingencies and recognizes such amounts only when the related contingencies have been resolved and the amounts are realized or realizable. Accordingly, during the three- and six-month periods ended June 30, 2026, the Company recognized a net refund of $1,102 as a reduction of cost of products sold, representing the recovery of tariff costs previously recognized in earnings. The tariff costs related to the refund recognized as a reduction of cost of products sold were not charged to customers and therefore not payable to customers. Additional refunds received related to tariff costs capitalized in inventory on hand at June 30, 2026 were recorded as a reduction of inventory and will be recognized in cost of products sold as the related inventory is sold in future periods. The refund was received in cash during the quarter.
The Company continues to evaluate potential claims for additional IEEPA tariff refunds. Additional recoveries remain subject to governmental review, claim validation, administrative processing and ongoing legal proceedings. Accordingly, as of June 30, 2026, the Company had not recorded a receivable or recognized any amounts related to potential future IEEPA tariff recoveries as realization of such amounts is not considered sufficiently probable at this time.
Recent Accounting Guidance Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for the Company’s annual reporting period beginning January 1, 2027, and interim reporting periods beginning January 1, 2028, with early adoption permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its consolidated financial statements.
|
2. |
DEBT |
On October 31, 2024, Ultralife, SWE, CLB, Excell USA, and Electrochem, as borrowers, and certain other subsidiaries of the Company, entered into a new Credit and Security Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent (the “New Credit Agreement”). The proceeds of the loans under the New Credit Agreement were used, in part, to repay outstanding indebtedness under the Company’s then existing Credit and Security Agreement with KeyBank (the “Amended Credit Agreement”).
The New Credit Agreement, among other things, provides in its term loan provisions for a
Upon closing of the acquisition of all issued and outstanding shares of Electrochem on October 31, 2024, the Company borrowed the full amount of the Term Loan Facility.
As of June 30, 2026, the Company had $
The New Credit Agreement also provides under its revolving credit provisions for revolving loans, letters of credit, and swing loans (“Revolving Credit Facility”). Upon the effectiveness of the New Credit Agreement, any amounts outstanding under letters of credit issued pursuant to the Amended Credit Agreement became issued under the New Credit Agreement. The availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on October 31, 2029.
The Company may voluntarily prepay principal amounts outstanding under the New Credit Agreement at any time subject to certain advance notifications and other restrictions.
In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated fixed charge coverage ratio, as defined in the New Credit Agreement, of equal to or greater than
Borrowings under the New Credit Agreement are secured by substantially all the assets of the Company and certain of its present and future subsidiaries who are or become parties to, or guarantors under the New Credit Agreement.
Interest will accrue on outstanding indebtedness under the Term Loan Facility and Revolving Credit Facilities at a variable rate of interest based on designated interest rate benchmarks plus a varying margin determined by reference to the consolidated senior leverage ratio in effect from time to time. Our borrowing rate was
The Company must pay a fee of twenty, twenty-five or thirty basis points (depending on the consolidated senior leverage ratio in effect from time to time) based on the average daily unused availability under the Revolving Credit Facility.
The Company must make payments to the extent borrowings exceed the maximum amount then permitted to be borrowed and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.
Future minimum principal repayment obligations on our New Credit Agreement as of June 30, 2026 are as follows:
|
2026 |
$ | |||
|
2027 |
||||
|
2028 |
||||
|
2029 |
||||
|
Total |
$ |
|
3. |
EARNINGS PER SHARE |
Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities when the average market price exceeds the exercise price of the securities, if any, and is calculated using the treasury stock method.
For the three-month period ended June 30, 2026, there were
There were
For the six-month period ended June 30, 2026, there were
There were
|
4. |
SUPPLEMENTAL BALANCE SHEET INFORMATION |
Fair Value Measurements and Disclosures
The fair value of financial instruments approximated their carrying values at June 30, 2026, and December 31, 2025. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments. The carrying value of long-term debt approximates fair value, as the variable interest rates approximate current market rates.
Inventories, Net
Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:
|
June 30, |
December 31, |
|||||||
|
2026 |
2025 |
|||||||
|
Raw materials |
$ | $ | ||||||
|
Work in process |
||||||||
|
Finished goods |
||||||||
|
Total |
$ | $ | ||||||
Property, Plant and Equipment, Net
Major classes of property, plant and equipment consisted of the following:
|
June 30, |
December 31, |
|||||||
|
2026 |
2025 |
|||||||
|
Land |
$ |
$ | ||||||
|
Buildings and leasehold improvements |
||||||||
|
Machinery and equipment |
||||||||
|
Furniture and fixtures |
||||||||
|
Computer hardware and software |
||||||||
|
Construction in process |
||||||||
|
Less: Accumulated depreciation |
( |
) | ( |
) | ||||
|
Property, plant and equipment, net |
$ | $ | ||||||
Depreciation expense for property, plant and equipment was as follows:
|
Three-month period ended |
Six-month period ended |
|||||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
|||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
Depreciation expense |
$ | $ | $ | $ | ||||||||||||
Goodwill
The following table summarizes the goodwill activity by segment for the six-month period ended June 30, 2026:
| Battery &
Energy |
Communications |
|||||||||||
|
Products |
Systems |
Total |
||||||||||
|
Balance – December 31, 2025 |
$ | $ | $ | |||||||||
|
Effect of foreign currency translation |
( |
) | ( |
) | ||||||||
|
Balance – June 30, 2026 |
$ | $ | $ | |||||||||
Other Intangible Assets, Net
The composition of other intangible assets was:
|
at June 30, 2026 |
||||||||||||
|
Accumulated |
||||||||||||
|
Cost |
Amortization |
Net |
||||||||||
|
Customer relationships |
$ | $ | $ | |||||||||
|
Patents and technology |
||||||||||||
|
Other |
||||||||||||
|
Total other intangible assets |
$ | $ | $ | |||||||||
|
at December 31, 2025 |
||||||||||||
|
Accumulated |
||||||||||||
|
Cost |
Amortization |
Net |
||||||||||
|
Customer relationships |
$ | $ | $ | |||||||||
|
Patents and technology |
||||||||||||
|
Other |
||||||||||||
|
Total other intangible assets |
$ | $ | $ | |||||||||
The change in the cost of total intangible assets from December 31, 2025, to June 30, 2026, is the effect of foreign currency translations.
Amortization expense for other intangible assets was as follows:
|
Three-month period ended |
Six-month period ended |
|||||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
|||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
Amortization included in: |
||||||||||||||||
|
Selling, general and administrative |
$ | $ | $ | $ | ||||||||||||
|
Research and development |
||||||||||||||||
|
Total amortization expense |
$ | $ | $ | $ | ||||||||||||
|
5. |
STOCK-BASED COMPENSATION |
We recorded non-cash stock compensation expense in each period as follows:
|
Three-month period ended |
Six-month period ended |
|||||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
|||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
Stock options |
$ | $ | $ | $ | ||||||||||||
|
Restricted stock |
( |
) | ||||||||||||||
|
Total |
$ | $ | $ | $ | ||||||||||||
We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of June 30, 2026, there was $
The following table summarizes stock option activity for the six-month period ended June 30, 2026:
|
Number of Shares |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Term (years) |
Aggregate Intrinsic Value |
|||||||||||||
|
Outstanding at January 1, 2026 |
$ | |||||||||||||||
|
Granted |
$ | |||||||||||||||
|
Exercised |
( |
) | $ | |||||||||||||
|
Forfeited or expired |
( |
) | $ | |||||||||||||
|
Outstanding at June 30, 2026 |
$ | $ | ||||||||||||||
|
Vested and expected to vest at June 30, 2026 |
$ | $ | ||||||||||||||
|
Exercisable at June 30, 2026 |
$ | $ | ||||||||||||||
Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended June 30, 2026, and June 30, 2025, was $
Restricted stock awards vest in equal annual installments over three (
|
6. |
INCOME TAXES |
Our effective tax rate for the six-month periods ended June 30, 2026, and 2025 was
On July 4, 2025, the One Big Beautiful Bill Act was signed into law in the United States which includes a broad range of tax provisions affecting businesses. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The Company has included the estimated impacts of the bill in the consolidated financial statements for the three-month and six-month periods ended June 30, 2026.
As of December 31, 2025, our federal net operating loss (“NOL”) carryforwards, state net operating loss carryforwards, and federal general business tax credit carryforwards were $
As of June 30, 2026, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $
As of June 30, 2026, we have not recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.
As of June 30, 2026, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.
There were no unrecognized tax benefits related to uncertain tax positions at June 30, 2026, and December 31, 2025.
As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2022 thru 2024 remain subject to IRS examination. Our U.S. tax matters for 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2015 thru 2024 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2015 through 2024 remain subject to examination by the respective foreign tax jurisdiction authorities.
|
7. |
OPERATING LEASES |
The Company has operating leases predominantly for operating facilities. As of June 30, 2026, the remaining lease terms on our operating leases range from approximately one (
The components of lease expense for the current and prior-year comparative periods were as follows:
|
Three-months ended |
Six-months ended |
|||||||||||||||
|
June 30, 2026 |
June 30, 2025 |
June 30, 2026 |
June 30, 2025 |
|||||||||||||
|
Operating lease cost |
$ | $ | $ | $ | ||||||||||||
|
Variable lease cost |
||||||||||||||||
|
Total lease cost |
$ | $ | $ | $ | ||||||||||||
Supplemental cash flow information related to leases was as follows:
|
Six-month period ended June 30, |
||||||||
|
2026 |
2025 |
|||||||
|
Cash paid for amounts included in the measurement of lease liabilities: |
||||||||
|
Operating cash flows from operating leases |
$ | $ | ||||||
|
Right-of-use assets obtained in exchange for lease liabilities: |
$ | $ | ||||||
Supplemental consolidated balance sheet information related to leases was as follows:
|
Balance sheet classification |
June 30, 2026 |
December 31, 2025 |
|||||||
|
Assets: |
|||||||||
|
Operating lease right-of-use asset |
Other noncurrent assets |
$ | $ | ||||||
|
Liabilities: |
|||||||||
|
Current operating lease liability |
Accrued expenses and other current liabilities |
$ | $ | ||||||
|
Operating lease liability, net of current portion |
Other noncurrent liabilities |
||||||||
|
Total operating lease liability |
$ | $ | |||||||
|
Weighted-average remaining lease term (years) |
|||||||||
|
Weighted-average discount rate |
% | % | |||||||
Future minimum lease payments as of June 30, 2026, are as follows:
|
Maturity of operating lease liabilities |
||||
|
2026 |
$ | |||
|
2027 |
||||
|
2028 |
||||
|
2029 |
||||
|
2030 |
||||
|
Thereafter |
||||
|
Total lease payments |
||||
|
Less: Imputed interest |
( |
) | ||
|
Present value of remaining lease payments |
$ |
|
8. |
COMMITMENTS AND CONTINGENCIES |
Purchase Commitments
As of June 30, 2026, we have made commitments to purchase approximately $
Product Warranties
We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first six months of 2026 and 2025 were as follows:
|
Six-month period ended June 30, |
||||||||
|
2026 |
2025 |
|||||||
|
Accrued warranty obligations – beginning |
$ | $ | ||||||
|
Accruals for warranties issued |
||||||||
|
Settlements made |
( |
) | ( |
) | ||||
|
Accrued warranty obligations – ending |
$ | $ | ||||||
Contingencies and Legal Matters
We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.
|
9. |
REVENUE RECOGNITION |
Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.
Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (
As of June 30, 2026, there was deferred revenue on extended warranty contracts of $
As of December 31, 2025, there was deferred revenue on extended warranty contracts of $
As of June 30, 2026, and December 31, 2025, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.
|
10. |
BUSINESS SEGMENT INFORMATION |
Operating segments represent a component of the Company that engages in business activities from which it may recognize revenues and incur expenses whose operating results are regularly reviewed by the public entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. Upon identification of operating segments, the Company determines which of those operating segments are required to be presented as reportable segments based on the quantitative thresholds.
We structure our operations primarily around the products we sell and report our financial results in the following two reportable segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design.
Our CODM is Mike Manna, President & Chief Executive Officer. Both of our operating segments are regularly reviewed by the CODM through weekly revenue, gross margin and consolidated financial forecast updates, bi-weekly business and financial reviews to assess business performance, top priorities, utilization of resources and to regularly communicate with segment management, who are part of the CODM’s executive leadership team, and monthly meetings with the executive leadership team. In his role as CODM, Mr. Manna is deeply involved in business operations through daily updates by the segment management and ongoing financial, revenue and operations discussions.
The primary financial measures used by the CODM to monitor and evaluate resource allocation and the performance of the operating segments is segment contribution, as defined by gross profit less direct selling, general and administrative (“SG&A”) and research and development expenses. This metric is used as a consistent benchmark for comparison across reporting periods.
The significant segment expenses regularly reviewed by the CODM and included in segment contribution are cost of products sold and direct R&D and SG&A expenses. There are no other segment items included in segment contribution beyond the significant expenses disclosed.
Corporate general and administrative (“G&A”) expenses, including costs associated with our acquisitions, include corporate functions including board of directors, executive officers, accounting & finance, human resources, legal, information technology and their related functional expenses. These costs are not directly allocable to the operating segments.
The CODM does not review segment assets at a level other than that presented in the Company’s consolidated balance sheets.
Three-month period ended June 30, 2026:
|
Battery & Energy Products |
Communications Systems |
Corporate |
Total |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Cost of products sold |
( |
) | ( |
) | ( |
) | ||||||||||
|
Gross profit |
||||||||||||||||
|
Direct SG&A expenses |
( |
) | ( |
) | - | ( |
) | |||||||||
|
Research and development |
( |
) | ( |
) | ( |
) | ||||||||||
|
Segment contribution |
- | |||||||||||||||
|
Corporate G&A expenses |
(2,499 | ) | (2,499 | ) | ||||||||||||
|
Operating income |
||||||||||||||||
|
Other expenses, net |
( |
) | ( |
) | ||||||||||||
|
Income tax provision |
( |
) | ( |
) | ||||||||||||
|
Non-controlling interest |
||||||||||||||||
|
Net income attributable to Ultralife Corporation |
$ | |||||||||||||||
|
Total assets |
$ | $ | $ | $ | ||||||||||||
|
Depreciation and amortization of intangible assets |
$ | $ | $ | $ | ||||||||||||
Three-month period ended June 30, 2025:
|
Battery & Energy Products |
Communications Systems |
Corporate |
Total |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Cost of products sold |
( |
) | ( |
) | ( |
) | ||||||||||
|
Gross profit |
||||||||||||||||
|
Direct SG&A expenses |
( |
) | ( |
) | - | ( |
) | |||||||||
|
Research and development |
( |
) | ( |
) | ( |
) | ||||||||||
|
Segment contribution |
( |
) | - | |||||||||||||
|
Corporate G&A expenses |
(2,619 | ) | (2,619 | ) | ||||||||||||
|
Operating income |
||||||||||||||||
|
Other expenses, net |
( |
) | ( |
) | ||||||||||||
|
Income tax provision |
( |
) | ( |
) | ||||||||||||
|
Non-controlling interest |
||||||||||||||||
|
Net income attributable to Ultralife Corporation |
$ | |||||||||||||||
|
Total assets |
$ | $ | $ | $ | ||||||||||||
|
Depreciation and amortization of intangible assets |
$ | $ | $ | $ | ||||||||||||
Six-month period ended June 30, 2026:
|
Battery & Energy Products |
Communications Systems |
Corporate |
Total |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Cost of products sold |
( |
) | ( |
) | ( |
) | ||||||||||
|
Gross profit |
||||||||||||||||
|
Direct SG&A expenses |
( |
) | ( |
) | - | ( |
) | |||||||||
|
Research and development |
( |
) | ( |
) | ( |
) | ||||||||||
|
Segment contribution |
( |
) | - | |||||||||||||
|
Corporate G&A expenses |
(5,403 | ) | (5,403 | ) | ||||||||||||
|
Operating income |
||||||||||||||||
|
Other expenses, net |
( |
) | ( |
) | ||||||||||||
|
Income tax provision |
( |
) | ( |
) | ||||||||||||
|
Non-controlling interest |
||||||||||||||||
|
Net income attributable to Ultralife Corporation |
$ | |||||||||||||||
|
Total assets |
$ | $ | $ | $ | ||||||||||||
|
Depreciation and amortization of intangible assets |
$ | $ | $ | $ | ||||||||||||
Six-month period ended June 30, 2025:
|
Battery & Energy Products |
Communications Systems |
Corporate |
Total |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Cost of products sold |
( |
) | ( |
) | ( |
) | ||||||||||
|
Gross profit |
||||||||||||||||
|
Direct SG&A expenses |
( |
) | ( |
) | - | ( |
) | |||||||||
|
Research and development |
( |
) | ( |
) | ( |
) | ||||||||||
|
Segment contribution |
( |
) | - | |||||||||||||
|
Corporate G&A expenses |
(5,330 | ) | (5,330 | ) | ||||||||||||
|
Operating income |
||||||||||||||||
|
Other expenses, net |
( |
) | ( |
) | ||||||||||||
|
Income tax provision |
( |
) | ( |
) | ||||||||||||
|
Non-controlling interest |
( |
) | ( |
) | ||||||||||||
|
Net income attributable to Ultralife Corporation |
$ | |||||||||||||||
|
Total assets |
$ | $ | $ | $ | ||||||||||||
|
Depreciation and amortization of intangible assets |
$ | $ | $ | $ | ||||||||||||
The following tables disaggregate our business segment revenues by major source and geography.
Commercial and Government/Defense Revenue Information:
Three-month period ended June 30, 2026:
|
Total Revenue |
Commercial |
Government/ Defense |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Three-month period ended June 30, 2025:
|
Total Revenue |
Commercial |
Government/ Defense |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Six-month period ended June 30, 2026:
|
Total Revenue |
Commercial |
Government/ Defense |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Six-month period ended June 30, 2025:
|
Total Revenue |
Commercial |
Government/ Defense |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
U.S. and Non-U.S. Revenue Information1:
Three-month period ended June 30, 2026:
|
Total Revenue |
United States |
Non-United States |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Three-month period ended June 30, 2025:
|
Total Revenue |
United States |
Non-United States |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Six-month period ended June 30, 2026:
|
Total Revenue |
United States |
Non-United States |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Six-month period ended June 30, 2025:
|
Total Revenue |
United States |
Non-United States |
||||||||||
|
Battery & Energy Products |
$ | $ | $ | |||||||||
|
Communications Systems |
||||||||||||
|
Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This report contains certain forward-looking statements and information that are based on the beliefs of management as well as assumptions made by management and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, uncertain global economic conditions including the impact of inflation, tariffs, interest rates and supply chain disruptions affecting our business, revenues and earnings adversely; our reliance on certain key customers for a significant portion of our revenues; reductions or delays in U.S. and foreign military spending; our efforts to develop new products or new commercial applications for our products could be prolonged; potential disruptions or delays in our supply of raw materials and components or material increases in their costs due to business conditions, new or additional tariffs, global conflicts, weather, sourcing requirements or other factors not under our control; our resources being overwhelmed by our growth; our ability to recruit and retain top management and key personnel; breaches in information systems security and other disruptions in our information technology systems; fluctuations in the price of oil and the resulting impact on the demand for downhole drilling; the unique risks associated with our China operations; possible future declines in demand for the products that use our batteries or communications systems; safety risks, including the risk of fire inherent in the manufacture, use and transportation of Lithium batteries; variability in our quarterly and annual results and the price of our common stock; purchases by our customers of product quantities not meeting the volume expectations in our supply agreements; rising interest rates increasing the cost of our variable borrowings; our inability to comply with changes to the regulations for the shipment of our products; our entrance into new end-markets which could lead to additional financial exposure; litigation or claims resulting in negative optics in the markets we serve and increased costs; the potential of future pandemics that may arise, causing delays in the manufacture and delivery of our mission critical products to end customers; potential costs attributable to the warranties we supply with our products and services; negative publicity concerning Lithium-ion batteries; rules and procedures regarding contracting with the U.S. and foreign governments; our exposure to foreign currency fluctuations; our ability to utilize our net operating loss carryforwards; the risk that we are unable to protect our proprietary and intellectual property; our ability to comply with government regulations including the use of “conflict minerals”; possible impairments of our goodwill and other intangible assets; known and unknown environmental matters; possible audits of our contracts by the U.S. and foreign governments and their respective defense agencies; exposure to possible violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act or other anti-corruption laws; and other risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements described herein. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “seek,” “project,” “intend,” “plan,” “may,” “will,” “should,” “foresee,” “could,” “likely,” or words of similar import are intended to identify forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025.
Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements do not guarantee future performance and that our actual results of operations, financial condition and liquidity and developments in the industries in which we operate may differ materially from those made in or suggested by the forward-looking statements contained herein. In addition, even if our results of operations, financial condition and liquidity and the development of the industries in which we operate are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements that we make herein speak only as of the date of those statements, and we undertake no obligation to update those statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim any obligation to update any risk factors or to publicly announce the results of any revisions to any of the forward-looking statements to reflect new information or risks, future events or other developments.
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the consolidated financial statements and notes thereto in Part I, Item 1 of this Form 10-Q, and the consolidated financial statements and notes thereto and risk factors in our Annual Report on Form 10-K for the year ended December 31, 2025.
The financial information in this MD&A is presented in thousands of dollars, except for share and per share amounts, unless otherwise specified.
General
We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design and manufacture power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems related to those product lines. We continually evaluate ways to grow, including the design, development and sale of new products, expansion of our sales force to penetrate new markets and territories, and seeking opportunities to expand through acquisitions.
We sell our products worldwide through a variety of trade channels, including original equipment manufacturers (“OEMs”), industrial and defense supply distributors, and directly to U.S. and foreign defense departments. Historically, we utilized the following brands, tradenames and trademarks (“sub-brands”) to promote our products in the markets we serve: Ultralife®, Ultralife Thin Cell®, Ultralife HiRate®, Ultralife & design®, LithiumPower®, LithiumPower & Design®, SMART CIRCUIT®, SMARTCIRCUIT®, SMART CIRCUIT & design®, SODIUMPOWER®, SODIUMPOWER (design)®, WE. ARE. POWER®, AMTI®, ABLE™, ACCUTRONICS™, ACCUPRO™, ENTELLION™, McDowell Research®, SWE DRILL-DATA®, SWE SEASAFE (& DESIGN)®, SWE SEASAFE DIRECT®, SWE SOUTHWEST ELECTRONIC ENERGY CORP®, SWE Southwest Electronic Energy Group®, Excell Battery Group™ and Criterion Gauge™, POW-R BMS®, POW-R TOTE® and Electrochem®. As explained below, our rebranding initiative will eliminate or de-emphasize our reference to the sub-brands going forward. We have sales, operations and product development facilities in North America, Europe and Asia.
As part of our strategic evolution, in October 2025, Ultralife decided to undergo a comprehensive rebranding initiative that consolidates all sub-brands under a singular, unified master brand – Ultralife. This move reflects our commitment to clarity, consistency and amplified brand equity across all markets. By streamlining our global identity, we aim to strengthen customer recognition, enhance operational efficiency and better align to our customers’ needs with a singular, powerful brand narrative. To this end, the Accutronics, Southwest Electronic Energy, Excell Battery, McDowell Research and AMTI brands will no longer be emphasized. The Electrochem brand will remain, but as a product brand on select primary cells. We believe this transformation will position Ultralife for ongoing growth and stronger market impact as we continue to lead in mission critical battery and RF power solutions. This rebranding initiative had a non-cash impact of $12,181 to reduce the value of our tradename and trademark intangible assets recorded during our 2025 fourth quarter.
We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that segment contribution, defined as gross profit less direct selling, general and administrative (“SG&A”) and research and development expenses, is the best indicator of segment performance. As such, we report segment results at the segment contribution level. (See Note 10 in the notes to consolidated financial statements contained in Item 1 of this Form 10-Q.)
Our website address is www.ultralifecorporation.com. We make available free of charge via a hyperlink on our website (see Investors link on the website) our annual reports on Form 10-K, proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports and statements as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (“SEC”). We will provide copies of these reports upon written request to the attention of Philip A. Fain, CFO, Treasurer and Secretary, Ultralife Corporation, 2000 Technology Parkway, Newark, New York, 14513. Our filings with the SEC are also available through the SEC website at www.sec.gov or at the SEC Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or by calling 1-800-SEC-0330.
Overview
Consolidated revenues of $47,943 for the three-month period ended June 30, 2026, decreased by $618 or 1.3%, from $48,561 for the three-month period ended June 30, 2025, reflecting a 4.7% decline in commercial sales partially offset by a 5.0% increase in government/defense sales.
Gross profit was $13,866, or 28.9% of revenue, for the three-month period ended June 30, 2026, compared to $11,601, or 23.9% of revenue, for the same quarter a year ago. The 500-basis point increase primarily resulted from favorable sales product mix and the net refund of IEEPA tariffs which had been recognized as net costs in previous periods.
Operating expenses were $10,429 for the three-month period ending June 30, 2026, compared to $9,345 for the three-month period ended June 30, 2025, reflecting an increase in new product development costs related to continued investment in our product offering and certain one-time, non-recurring costs which amounted to $884 for the current period which represents a $558 increase over the non-recurring costs incurred in the prior year. Operating expenses for the 2026 period were 21.8% of revenue compared to 19.2% of revenue for the year-earlier period.
Operating income for the three-month period ended June 30, 2026, was $3,437, or 7.2% of revenues, compared to $2,256, or 4.6% of revenues, for the year-earlier period. The increase in operating income primarily resulted from the favorable product mix for our Battery & Energy Products and Communications Systems segments and the net refund of IEEPA tariffs previously paid and recognized as costs in prior periods, partially offset by an increase in one-time, non-recurring costs.
Other expense for the second quarter of 2026 was $451 compared to $1,143 for the year-earlier quarter. The decrease for the 2026 period primarily reflects lower interest expense for the financing of our Electrochem acquisition with the continued paydown of the related term loan, the current period estimated portion of a refundable tax credit for certain qualifying battery cells and packs we manufacture under the 45X Advanced Manufacturing Production Tax Credit, established by the Inflation Reduction Act and running through 2032, and more favorable foreign currency rates in the current period.
Net income attributable to Ultralife Corporation was $2,543, or $0.15 per share – basic and diluted, for the three-month period ended June 30, 2026, compared to $879, or $0.05 per share – basic and diluted, for the three-month period ended June 30, 2025.
Adjusted EBITDA, defined as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing operations, amounted to $6,148, or 12.8% of revenues, for the second quarter of 2026, compared to $4,113, or 8.5% of revenues, for the second quarter of 2025. See the section “Adjusted EBITDA” on page 26 for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.
We remain intently focused on converting our long-term new product development efforts into revenue, maintaining a strong focus on operational efficiency initiatives to improve our gross margins and advancing vertical integration in the oil & gas segment. We believe these improvements, along with execution and replenishment of our backlog, position Ultralife to deliver sustainable profitable growth generating incremental cash flow for 2026 to further reduce debt, support strategic capital expenditures, continue our investment in new product development and maximize the value of our global brand.
Results of Operations
Three-Month Periods Ended June 30, 2026, and June 30, 2025
Revenues. Consolidated revenues for the three-month period ending June 30, 2026, were $47,943, a decrease of $618, or 1.3%, from $48,561 for the three-month period ended June 30, 2025. Overall, commercial sales decreased 4.7% and government/defense sales increased 5.0%.
Battery & Energy Products revenues decreased $1,678, or 3.7%, from $45,867 for the three-month period ended June 30, 2025, to $44,189 for the three-month period ended June 30, 2026. The revenue decline was primarily attributable to a 4.7% decrease in commercial sales due to an 8.7% decrease in oil & gas and industrial sales, offsetting a 7.2% increase in medical battery sales, and a 1.4% decline in government/defense sales due to the shipment of a very large order for an allied country last year.
Communications Systems sales increased $1,060, or 39.3%, from $2,694 for the three-month period ended June 30, 2025, to $3,754 for the three-month period ended June 30, 2026, due primarily to the timing of orders.
Our total backlog, which consists of unfilled orders or contracts for shipments in future periods, exiting the second quarter of 2026 was $117.5 million, the highest level in the Company’s history, compared to $115.1 million exiting the first quarter of 2026 and $84.5 million exiting the second quarter of 2025.
Cost of Products Sold / Gross Profit. Cost of products sold totaled $34,077 for the quarter ended June 30, 2026, a decrease of $2,883, or 7.8%, from the $36,960 reported for the same three-month period a year ago. Consolidated cost of products sold as a percentage of total revenue decreased from 76.1% for the three-month period ended June 30, 2025, to 71.1% for the three-month period ended June 30, 2026. Correspondingly, consolidated gross margin increased from 23.9% for the three-month period ended June 30, 2025, to 28.9% for the three-month period ended June 30, 2026, primarily reflecting favorable sales product mix for both our Battery & Energy Products and Communications Systems segments and the net refund of IEEPA tariffs which had been recognized as net costs in previous periods. The net IEEPA refund in the second quarter of 2026 was $1,102, accounting for 230 basis point of gross margin for that period.
For our Battery & Energy Products segment, gross profit for the second quarter of 2026 was $12,503, an increase of $1,668 or 15.4% from gross profit of $10,835 for the second quarter of 2025. Battery & Energy Products’ gross margin of 28.3% increased by 470-basis points from the 23.6% gross margin for the year-earlier period, primarily due to sales mix and the net refund of IEEPA tariffs. The net refund accounted for 250 basis points of the year-over-year increase in gross margin.
For our Communications Systems segment, gross profit for the second quarter of 2026 was $1,363 or 36.3% of revenues, compared to gross profit of $766 or 28.4% of revenues for the second quarter of 2025. The 790-basis point increase in gross margin was primarily due to favorable sales mix.
Operating Expenses. Operating expenses for the three-month period ended June 30, 2026, were $10,429, an increase of $1,084 or 11.6% from the $9,345 for the three-month period ended June 30, 2025. The increase is primarily attributable to a 39.1% increase in new product development costs related to continued investment in our product offerings and the completion of certain one-time, non-recurring expenses of $884 primarily related to litigation expenses incurred for our cyber-insurance claim and certain consulting costs to help expedite gross margin improvement at our two largest manufacturing facilities. Non-recurring costs reported for the 2025 second quarter were $326 primarily representing litigation expenses for our cyber insurance claim and acquisition transition costs. Both periods reflected continued tight control over discretionary spending.
Overall, operating expenses were 21.8% of revenue for the quarter ending June 30, 2026, compared to 19.2% of revenue for the quarter ended June 30, 2025. Amortization expense associated with intangible assets related to our acquisitions was $268 for the second quarter of 2026 ($263 in selling, general and administrative expenses and $5 in research and development costs), compared with $410 for the second quarter of 2025 ($378 in selling, general, and administrative expenses and $32 in research and development costs). The year-over-year decline in amortization expenses resulted from our decision in the 2025 fourth quarter to undergo a comprehensive rebranding initiative that consolidates all sub-brands under a singular, unified master brand – Ultralife, and the ensuing write-down of tradenames and trademarks associated with our sub-brands during that period. Research and development costs were $3,225 for the three-month period ended June 30, 2026, an increase of $907 or 39.1%, from $2,318 for the three-month period ended June 30, 2025. The increase is attributable to an increase in new product development costs related to continued investment in our product offering as we aggressively pursue both government/defense and commercial opportunities. Selling, general, and administrative expenses were $7,204 for the three-month period ended June 30, 2026, an increase of $177 or 2.5% from $7,027 for the second quarter of 2025. The period-over-period increase was primarily attributable to the inclusion of certain one-time, non-recurring expenses of $884 primarily related to litigation expenses incurred for our cyber-insurance claim and the completion of consulting costs to help expedite gross margin improvement at our two largest manufacturing facilities.
Other Expense. Other expense totaled $451 for the three-month period ended June 30, 2026, compared to $1,143 for the three-month period ended June 30, 2025. Interest and financing expense decreased $153, or 15.4%, from $992 for the second quarter of 2025 to $839 for the comparable period in 2026 resulting from the continued paydown of the term loan financing of the Electrochem acquisition on October 31, 2024. Miscellaneous (income) expense amounted to ($388) for the second quarter of 2026 compared to $151 for the second quarter of 2025, primarily attributable to refundable tax credits for certain qualifying battery cells and packs we manufacture under the 45X Advanced Manufacturing Production Credit, established by the Inflation Reduction Act which runs through 2032. In addition, both periods reflect foreign exchange gains and losses due to fluctuations in foreign currency exchange rates.
Income Taxes. For the three-month period ended June 30, 2026, Ultralife recognized an income tax provision of $468, comprised of a current tax provision of $47 and a deferred tax provision of $421 which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. This compares to a tax provision of $243 comprised of a current tax benefit of $22 and a deferred tax provision of $265 for the three-month period ended June 30, 2025. Our effective tax rate was 15.7% for the second quarter of 2026 as compared to 21.8% for the second quarter of 2025, primarily attributable to the geographic mix of our operating results and other income recognized on the nontaxable refundable tax credits under the 45X Advanced Manufacturing Production Credit. See Note 6 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for additional information regarding our income taxes.
Net Income Attributable to Ultralife Corporation. Net income attributable to Ultralife Corporation was $2,543, or $0.15 per share – basic and diluted, for the three-month period ended June 30, 2026, compared to $879, or $0.05 per share – basic and diluted, for the three-month period ended June 30, 2025.
Weighted average shares outstanding used to compute diluted earnings per share increased from 16,656,408 for the second quarter of 2025 to 16,714,196 for the second quarter of 2026. The increase is attributable to stock option exercises since the second quarter. Dilutive shares of 55,268 were added to basic weighted average shares for the 2026 period compared to 21,856 for the 2025 period.
Six-Month Periods Ended June 30, 2026, and June 30, 2025
Revenues. Consolidated revenues for the six-month period ended June 30, 2026, were $95,388, a decrease of $3,919 or 3.9%, from $99,307 for the six-month period ended June 30, 2025. Overall, commercial sales decreased $3,259 or 5.1% and government/defense sales decreased $660 or 1.8%.
Battery & Energy Products revenues decreased $3,844, or 4.2%, from $92,188 for the six-month period ended June 30, 2025, to $88,344 for the six-month period ended June 30, 2026. The decrease is primarily attributable to a $3,259 or 5.1% decline in commercial sales and a $585 or a 2.0% decline in government/defense sales. The decrease in commercial sales was driven by a $2,265 or 12.7% decline in industrial sales and a $2,049 or 6.9% decline in oil & gas sales, partially offset by a $1,055 or 6.5% increase in medical battery sales. The overall decline in commercial sales was in large part a result of lost production days due to the failure of the substation providing power to our Newark, NY facility and winter blizzards and a prolonged shutdown to conduct a comprehensive physical inventory at our Raynham, MA facility during the first quarter of 2026. The government/defense sales decline was due to the shipment of a very large charger order for an allied country in the 2025 period.
Communications Systems revenues decreased $75 or 1.1%, from $7,119 for the six-month period ended June 30, 2025, to $7,044 for the six-month period ended June 30, 2026. The decrease was primarily attributable to shipments in the prior year to a major international defense contractor and the timing of expected orders in the current period.
Cost of Products Sold / Gross Profit. Cost of products sold totaled $71,412 for the six-month period ended June 30, 2026, a decrease of $3,549, or 4.7%, from the $74,961 reported for the same six-month period a year ago. Consolidated cost of products sold as a percentage of total revenue decreased from 75.5% for the six-month period ended June 30, 2025, to 74.9% for the six-month period ended June 30, 2026. Correspondingly, consolidated gross margin increased from 24.5% for the six-month period ended June 30, 2025, to 25.1% for the six-month period ended June 30, 2026, reflecting the net refund of IEEPA tariffs of $1,102 in the second quarter which had been recognized as net costs in previous periods.
For our Battery & Energy Products segment, gross profit for the 2026 period was $21,861, a decrease of $414 or 1.9% from gross profit of $22,275 for the 2025 period. Battery & Energy Products’ gross margin of 24.7% increased by 50-basis points from the 24.2% gross margin for the year-earlier period, primarily due to sales mix and the net refund of IEEPA tariffs.
For our Communications Systems segment, gross profit for the 2026 period was $2,115 or 30.0% of revenues, compared to gross profit of $2,071 or 29.1% of revenues for the 2025 period. The 90-basis point increase in gross margin was primarily due to favorable sales mix.
Operating Expenses. Operating expenses for the six-month period ended June 30, 2026, were $20,754, an increase of $2,063 or 11.0% from the $18,691 for the six-month period ended June 30, 2025. The increase is primarily attributable to a 31.0% increase in new product development costs related to continued investment in our product offerings and the completion of certain one-time, non-recurring expenses of $1,731, compared to $518 for the year-earlier quarter, primarily related to litigation expenses incurred for our cyber-insurance claim and certain consulting costs to help expedite gross margin improvement at our two largest manufacturing facilities. Both periods reflected continued tight control over discretionary spending.
Overall, operating expenses as a percentage of revenues were 21.8% for the six-month period ended June 30, 2026, compared to 18.8% for the six-month period ended June 30, 2025. Amortization expense associated with intangible assets related to our acquisitions was $535 for the first six months of 2026 ($525 in selling, general and administrative expenses and $10 in research and development costs), compared with $815 for the first six months of 2025 ($754 in selling, general, and administrative expenses and $61 in research and development costs). The year-over-year decline in amortization expenses resulted from our decision in the 2025 fourth quarter to undergo a comprehensive rebranding initiative that consolidates all sub-brands under a singular, unified master brand – Ultralife, and the ensuing write-down of tradenames and trademarks associated with out sub-brands during that period. Research and development costs were $6,186 for the six-month period ended June 30, 2026, an increase of $1,464 or 31.0 %, from $4,722 for the six months ended June 30, 2025. Selling, general, and administrative expenses increased $599, or 4.3%, from $13,969 for the first six months of 2025 to $14,568 for the first six months of 2026. The period-over-period increase was primarily attributable to the inclusion of certain one-time, non-recurring expenses primarily related to litigation expenses incurred for our cyber-insurance claim and the completion of consulting costs to help expedite gross margin improvement at our two largest manufacturing facilities.
Other Expense. Other expense totaled $899 for the six-month period ended June 30, 2026, compared to $2,096 for the six-month period ended June 30, 2025. Interest and financing expense decreased $317, or 15.7%, from $2,024 for the first half of 2025 to $1,707 for the comparable period in 2026 resulting from the continued paydown of the term loan financing of the Electrochem acquisition on October 31, 2024. Miscellaneous (income) expense amounted to ($808) for the first half of 2026 compared to $72 for the first half of 2025, primarily attributable to refundable tax credits for certain qualifying battery cells and packs we manufacture under the 45X Advanced Manufacturing Production Credit, established by the Inflation Reduction Act which runs through 2032. In addition, both periods reflect foreign exchange gains and losses due to fluctuations in foreign currency exchange rates.
Income Taxes. The income tax provision for the 2026 six-month period was $276 compared to $810 for the 2025 six-month period. Our effective tax rate decreased to 11.9% from 22.8% for the 2025 period, primarily attributable to the geographic mix of our operating results and other income recognized on the nontaxable refundable tax credits under the 45X Advanced Manufacturing Production Credit. The income tax provision for the first six months of 2026 is comprised of a $183 current tax provision for taxes expected to be paid on income primarily in foreign jurisdictions and a $93 deferred tax provision which primarily represents non-cash charges for U.S. income taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. For the comparable 2025 period, the income tax provision was comprised of a $201 current provision for taxes expected to be paid on income primarily in foreign jurisdictions and a $609 deferred tax provision which primarily represents non-cash charges for U.S. taxes that we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. See Note 6 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for additional information regarding our income taxes.
Net Income Attributable to Ultralife. Net income attributable to Ultralife was $2,092, or $0.13 per share – basic and diluted for the six-month period ended June 30, 2026, compared to $2,744, or $0.17 per share – basic and diluted, for the six-month period ended June 30, 2025.
Weighted average shares outstanding used to compute diluted earnings per share increased from 16,671,000 for the first six months of 2025 to 16,702,714 for the first six months of 2026. The increase is attributable to stock option exercises since the second quarter of 2025, a slight increase in the average stock price used to compute diluted shares from $6.36 for the six-month period ended June 30, 2025, to $6.43 for the six-month period ended June 30, 2026. Accordingly diluted shares of 44,992 were added to basic weighted average shares in 2026 compared to 37,237 in 2025.
Adjusted EBITDA
In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define adjusted EBITDA as net income (loss) attributable to Ultralife Corporation before interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We also use adjusted EBITDA as a supplemental measure to review and assess our operating performance and to enhance comparability between periods. We believe the use of adjusted EBITDA facilitates investors’ understanding of operating performance from period to period by backing out potential differences caused by variations in such items as capital structures (affecting relative interest expense and stock-based compensation expense), the amortization of intangible assets acquired through our business acquisitions (affecting relative amortization expense and provision (benefit) for income taxes), the age and book value of facilities and equipment (affecting relative depreciation expense) and one-time charges/benefits relating to income taxes. Adjusted EBITDA should not be considered in isolation, as a substitute for, or superior to net income, operating income, cash flows from operating activities or any other measure of financial performance prepared in accordance with GAAP. We also present adjusted EBITDA from operations because we believe it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. We reconcile adjusted EBITDA to net income (loss) attributable to Ultralife Corporation, the most comparable financial measure under GAAP.
We use adjusted EBITDA in our decision-making processes relating to the operation of our business together with GAAP financial measures such as operating (loss) income. We believe that adjusted EBITDA permits a comparative assessment of our operating performance, relative to our performance based on our GAAP results, while eliminating the effects of depreciation and amortization, which may vary from period to period without any correlation to underlying operating performance, and of stock-based compensation, which is a non-cash expense that varies widely among companies. We believe that by presenting adjusted EBITDA, we assist investors in gaining a better understanding of our business on a going forward basis. We provide information relating to our adjusted EBITDA so that securities analysts, investors and other interested parties have the same data that we employ in assessing our overall operations. We believe that trends in our adjusted EBITDA are a valuable indicator of our operating performance on a consolidated basis and of our ability to produce operating cash flows to fund working capital needs, to service debt obligations and to fund capital expenditures.
The term adjusted EBITDA is not defined under GAAP and is not a measure of operating (loss) income, operating performance or liquidity presented in accordance with GAAP. Our adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, adjusted EBITDA should not be considered in isolation or as a substitute for net income attributable to Ultralife Corporation or other consolidated statement of operations data prepared in accordance with GAAP. Some of these limitations include, but are not limited to, the following:
|
● |
Adjusted EBITDA does not reflect (1) our cash expenditures or future requirements for capital expenditures or contractual commitments; (2) changes in, or cash requirements for, our working capital needs; (3) the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt; (4) income taxes or the cash requirements for any tax payments; and (5) all of the costs associated with operating our business; |
|
● |
Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and adjusted EBITDA from continuing operations does not reflect any cash requirements for such replacements; |
|
● |
While stock-based compensation is a component of cost of products sold and operating expenses, the impact on our consolidated financial statements compared to other companies can vary significantly due to such factors as assumed life of the stock-based awards and assumed volatility of our common stock; and |
|
● |
Other companies may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. |
We compensate for these limitations by relying primarily on our GAAP results and using adjusted EBITDA only on a supplemental basis. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.
Adjusted EBITDA is calculated as follows for the periods presented:
|
Three-Month Period Ended |
Six-Month Period Ended |
|||||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
|||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
Net income attributable to Ultralife Corporation |
$ | 2,543 | $ | 879 | $ | 2,092 | $ | 2,744 | ||||||||
|
Adjustments: |
||||||||||||||||
|
Interest expense |
839 | 992 | 1,707 | 2,024 | ||||||||||||
|
Income tax provision |
468 | 243 | 276 | 810 | ||||||||||||
|
Depreciation expense |
1,056 | 1,008 | 2,110 | 1,958 | ||||||||||||
|
Amortization expense |
268 | 410 | 535 | 815 | ||||||||||||
|
Stock-based compensation expense |
90 | 235 | 89 | 462 | ||||||||||||
|
Other non-recurring costs |
884 | 326 | 1,731 | 518 | ||||||||||||
|
One-Time events impacting production |
- | - | 817 | - | ||||||||||||
|
Severance cost for plant closure |
- | - | - | 150 | ||||||||||||
|
Non-cash purchase accounting adjustments |
- | 20 | - | 80 | ||||||||||||
|
Adjusted EBITDA |
$ | 6,148 | $ | 4,113 | $ | 9,357 | $ | 9,561 | ||||||||
Liquidity and Capital Resources
As of June 30, 2026, cash totaled $6,663, as compared to $9,345 at December 31, 2025. The decrease in cash was largely attributable to payments totaling $5,125 against the outstanding principal on our Term Loan during the first half of 2026.
For the six-month period ended June 30, 2026, cash generated from operations was $3,444, as compared to $9,303 generated for the six-month period ended June 30, 2025. For the 2026 period, cash generated from operations was comprised of net income of $2,047 plus non-cash items totaling $2,959 for depreciation, amortization, stock-based compensation, and deferred taxes, offset by decrease of $1,562 attributable to working capital.
Cash used in investing activities for the six months ended June 30, 2026, was $1,223 for capital expenditures, primarily reflecting investments in equipment for new products transitioning to higher-volume manufacturing.
Cash used in financing activities for the six months ended June 30, 2026, was $5,089, representing a $5,125 reduction in our outstanding debt partially offset by $36 of cash generated from employee stock option exercise proceeds during the period.
We continue to have significant U.S. net operating loss carryforwards available to utilize as an offset to future taxable income. See Note 6 to the consolidated financial statements in Item 1 of Part 1 of this Form 10-Q for additional information.
Going forward, we expect positive operating cash flow and the availability of borrowings under our Revolving Credit Facility will be sufficient to meet our general funding requirements for the foreseeable future.
To provide flexibility in accessing the capital markets, on March 30, 2021, the Company filed a shelf registration statement on Form S-3 (File No. 333-254846) (the “Prior Registration Statement”) registering securities in an aggregate amount of $100,000,000. None of the $100,000,000 of registered securities were sold under the Prior Registration Statement (the “Unsold Securities”). Under the rules of the Securities and Exchange Commission (the “SEC”) the Prior Registration Statement was set to expire on April 2, 2024. Therefore, on March 29, 2024, the Company filed a new shelf registration statement on Form S-3 (File No. 333-278360) (the “New Registration Statement”) to replace the Prior Registration Statement. The New Registration Statement includes all $100,000,000 of the Unsold Securities registered on the Prior Registration Statement. The SEC declared the New Registration Statement effective May 7, 2024. Pursuant to Rule 415(a)(6) under Securities Act of 1933, as amended (the “Securities Act”), the offering of the Unsold Securities under the Prior Registration Statement was deemed terminated as of the date of effectiveness of the New Registration Statement. Upon the filing of an appropriate prospectus supplement or supplements under the New Registration Statement, we may offer and sell our securities from time to time in one or more offerings, at our discretion. We intend to use the net proceeds resulting from any sales of these securities for general corporate purposes which may include, but are not limited to, potential acquisitions of complementary businesses or technologies, strategic capital expenditures to expand and protect our competitive position, and investments in the development of transformational, competitively differentiated products for attractive growth markets.
Commitments
As of June 30, 2026, the Company had $45,125 outstanding on the Term Loan and no amounts outstanding on the Revolving Credit Facility. The Company was in full compliance with its debt covenants under the Revolving Credit Facility and Term Loan as of June 30, 2026.
As of June 30, 2026, we have made commitments to purchase approximately $301 of production machinery and equipment.
Critical Accounting Policies
Management exercises judgment in making important decisions pertaining to choosing and applying accounting policies and methodologies in many areas. Not only are these decisions necessary to comply with GAAP, but they also reflect management’s view of the most appropriate manner in which to record and report our overall financial performance. All accounting policies are important, and all policies described in Note 1 to the consolidated financial statements in our 2025 Annual Report on Form 10-K should be reviewed for a greater understanding of how our financial performance is recorded and reported.
During the first six months of 2026, there were no significant changes in the manner in which our significant accounting policies were applied or in which related assumptions and estimates were developed.
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Management, under the supervision and with the participation of our President and Chief Executive Officer (principal executive officer) and our Chief Financial Officer and Treasurer (principal financial officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this quarterly report. Management has concluded that our disclosure control and procedures were not effective as of June 30, 2026, because of the existing material weakness in our internal control over financial reporting as described below.
Notwithstanding the material weakness identified, management believes that the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with U.S. generally accepted accounting principles for each of the periods presented.
Material Weakness in Internal Control over Financial Reporting
Management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework (2013). Based on our evaluation, management concluded that there is a material weakness in our internal control over financial reporting. As a result of the material weakness identified, management has concluded that our internal control over financial reporting was not effective as of December 31, 2025. The material weakness was not yet fully remediated as of June 30, 2026.
A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.
A material weakness has been identified because remediation efforts initiated during the year ended December 31, 2025, relating to the material weakness identified during the year ended December 31, 2024, attributable to the need for additional personnel to provide a full complement of accounting and reporting expertise had not been in place and adequately documented for a sufficient period of time to allow management to conclude that the related controls were operating effectively. In addition, information technology general controls (ITGC) were not operating effectively to ensure that (i) access to applications and data, including the ability to make changes, was appropriately restricted to authorized personnel, and (ii) the activities of individuals with such access were adequately monitored. As a result, business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted.
Remediation Efforts to Address Material Weakness
Over the course of 2025, management implemented a remediation plan designed to address the material weakness identified during the year ended December 31, 2024, attributable to the need for additional personnel to provide a full complement of accounting and reporting expertise commensurate with the growth of the Company. The Company has significantly strengthened its finance and accounting team by adding a new oversight role and hiring additional highly experienced personnel including certified public accountants. The personnel actions taken include the naming of a Chief Accounting Officer with a backfill to the Corporate Controller role and filling the following positions: Director – Internal Audit & SOX Compliance, Manager – Corporate Accounting, Manager – Corporate Reporting & Consolidations, Controller – Electrochem, and Senior Management Accountant – Electrochem. Significant improvements in the design, execution and documentation of business process controls were implemented across our locations pursuant to our remediation plan during the second half of 2025 once the additional oversight was in place and additional personnel were hired; however, it was determined that certain business process controls were not in place and adequately documented for a sufficient period of time to allow management to conclude that the previously identified material weakness was fully remediated as of December 31, 2025.
During the first half of 2026 and through the date of this Quarterly Report on Form 10-Q, management continues to develop and is actively implementing corrective actions to remediate the identified ITGC deficiencies. The Company is conducting a comprehensive risk-based evaluation of user access to our key IT applications to ensure that access is appropriately administered. Access will be restricted to the extent possible, and monitoring or other mitigating controls will be implemented to address instances, if any, where system-level segregation may not be feasible. Steps have been taken to restrict certain user access and to evaluate activity logs through the period that such access was deemed to have not been appropriately restricted. Additionally, we are in the process of formalizing our user access reviews and requiring that they are performed on a more frequent and timely basis.
Remediation will be deemed complete once all corrective actions are fully implemented and in place for a sufficient period of time and further evaluation is performed, including testing, to conclude that our internal control over financial reporting is effective.
Changes in Internal Control Over Financial Reporting
Other than the remedial actions described above, there were no changes in our internal control over financial reporting (as defined in Securities Exchange Act Rule 13a-15(f)) that occurred during the fiscal quarter covered by this quarterly report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations of Effectiveness of Controls
Management, including our Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s disclosure controls and procedures or its internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that its objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Furthermore, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons or by the collusion of two or more persons. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of the effectiveness of controls to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
PART II.
Item 6. Exhibits
|
Exhibit Index |
Exhibit Description |
Incorporated by Reference from |
||
|
31.1 |
Rule 13a-14(a) / 15d-14(a) CEO Certifications |
Filed herewith |
||
|
31.2 |
Rule 13a-14(a) / 15d-14(a) CFO Certifications |
Filed herewith |
||
|
32 |
Section 1350 Certifications |
Furnished herewith |
||
|
101.INS |
Inline XBRL Instance Document |
Filed herewith |
||
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
Filed herewith |
||
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
Filed herewith |
||
|
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
Filed herewith |
||
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
Filed herewith |
||
|
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
Filed herewith |
||
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
Filed herewith |
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025, (ii) Consolidated Statements of Income and Comprehensive Income for the three and six months ended June 30, 2026 and 2025, (iii) Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025, (iv) Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025, and (v) Notes to Consolidated Financial Statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ULTRALIFE CORPORATION |
|||
|
(Registrant) |
|||
|
Date: August 7, 2026 |
By: |
/s/ Michael E. Manna |
|
|
Michael E. Manna |
|||
|
President and Chief Executive Officer |
|||
|
(Principal Executive Officer) |
|||
|
Date: August 7, 2026 |
By: |
/s/ Philip A. Fain |
|
|
Philip A. Fain |
|||
|
Chief Financial Officer and Treasurer |
|||
|
(Principal Financial Officer and |
|||
|
Principal Accounting Officer) |